List of Publications by Year in descending order

88 papers	9,321 citations	87723 38 h-index	53109 85 g-index
91 all docs	91 docs citations	91 times ranked	14500 citing authors

#	Article	IF	Citations
1	Cost-effectiveness acceptability curvesâ€“ facts, fallacies and frequently asked questions. Health Economics (United Kingdom), 2004, 13, 405-415.	0.8	754
2	An Introduction to Markov Modelling for Economic Evaluation. Pharmacoeconomics, 1998, 13, 397-409.	1.7	713
3	Review of statistical methods for analysing healthcare resources and costs. Health Economics (United Kingdom), 2011, 20, 897-916.	0.8	574
4	Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report. Value in Health, 2005, 8, 521-533.	0.1	567
5	Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research. PLoS Medicine, 2013, 10, e1001380.	3.9	561
6	Cost-Effectiveness Analysis Alongside Clinical Trials IIâ€"An ISPOR Good Research Practices Task Force Report. Value in Health, 2015, 18, 161-172.	0.1	539
7	Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Economics (United Kingdom), 1994, 3, 95-104.	0.8	487
8	Prognosis research strategy (PROGRESS) 1: A framework for researching clinical outcomes. BMJ, The, 2013, 346, e5595-e5595.	3.0	450
9	Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics (United Kingdom), 2005, 14, 339-347.	0.8	368
10	Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. , 1998, 7, 723-740.		323
11	Missing.... presumed at random: cost-analysis of incomplete data. Health Economics (United Kingdom), 2003, 12, 377-392.	0.8	280
12	Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. European Heart Journal, 2015, 36, 100-111.	1.0	241
13	Performance-Based Risk-Sharing Arrangementsâ€"Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force. Value in Health, 2013, 16, 703-719.	0.1	237
14	The Distribution of Health Care Costs and Their Statistical Analysis for Economic Evaluation. Journal of Health Services Research and Policy, 1998, 3, 233-245.	0.8	220
15	The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. Value in Health, 2016, 19, 921-928.	0.1	203
16	Cardiac Troponin T and Troponin I in the General Population. Circulation, 2019, 139, 2754-2764.	1.6	200
17	Value based pricing for NHS drugs: an opportunity not to be missed?. BMJ: British Medical Journal, 2008, 336, 251-254.	2.4	178
18	Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research and Policy, 2007, 12, 56-58.	0.8	155

#	Article	IF	Citations
19	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, The, 2018, 19, 562-578.	5.1	133
20	Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. Value in Health, 2016, 19, 704-719.	0.1	101
21	Comparison between High-Sensitivity Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort. Clinical Chemistry, 2018, 64, 1607-1616.	1.5	101
22	Sensitivity analysis in economic evaluation: A review of published studies. Health Economics (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.8	99
23	Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. American Heart Journal, 2016, 172, 160-169.	1.2	93
24	Parametric modelling of cost data: some simulation evidence. Health Economics (United Kingdom), 2005, 14, 421-428.	0.8	84
25	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVIDâ€19. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 735-750.	2.7	83
26	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. Cancer Research, 2020, 80, 5427-5434.	0.4	77
27	Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review. Health Technology Assessment, 2014, 18, v-vi, 1-175.	1.3	68
28	Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD. JAMA - Journal of the American Medical Association, 2018, 320, 1548.	3.8	67
29	Count the cost of disability caused by COVID-19. Nature, 2021, 593, 502-505.	13.7	64
30	Expanding access to HAART: a cost-effective approach for treating and preventing HIV. Aids, 2010, 24, 1929-1935.	1.0	63
31	Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models. Pharmacoeconomics, 2018, 36, 1421-1426.	1.7	63
32	Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. European Heart Journal, 2006, 27, 796-801.	1.0	57
33	Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart, 2007, 93, 1081-1086.	1.2	53
34	Comparison of behavioural activation with guided self-help for treatment of depression in adults with intellectual disabilities: a randomised controlled trial. Lancet Psychiatry,the, 2017, 4, 909-919.	3.7	52
35	Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics, 2005, 23, 529-536.	1.7	49
36	The Use of Probabilistic Decision Models in Technology Assessment. Applied Health Economics and Health Policy, 2004, 3, 79-89.	1.0	45

#	Article	IF	Citations
37	Long-Term Effects of Statin Treatment in Elderly People: Extended Follow-Up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PLoS ONE, 2013, 8, e72642.	1.1	41
38	SPOILT FOR CHOICE: IMPLICATIONS OF USING ALTERNATIVE METHODS OF COSTING HOSPITAL EPISODE STATISTICS. Health Economics (United Kingdom), 2012, 21, 1201-1216.	0.8	39
39	Population ageing and healthcare expenditure projections: new evidence from a time to death approach. European Journal of Health Economics, 2014, 15, 885-896.	1.4	38
40	The â€œHazardsâ€•of Extrapolating Survival Curves. Medical Decision Making, 2013, 33, 369-380.	1.2	36
41	Access with Evidence Development in the UK. Pharmacoeconomics, 2010, 28, 163-170.	1.7	33
42	Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1096-1104.	2.3	33
43	Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. Diabetologia, 2014, 57, 2513-2520.	2.9	30
44	Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. BMC Medicine, 2010, 8, 23.	2.3	29
45	The â€œEâ€•in Cost-Effectiveness Analyses. A Case Study of Omalizumab Efficacy and Effectiveness for Cost-Effectiveness Analysis Evidence. Annals of the American Thoracic Society, 2014, 11, S105-S111.	1.5	27
46	Cost-Effectiveness and Cost-Utility of Long-Term Management Strategies for Heartburn. Value in Health, 2002, 5, 312-328.	0.1	26
47	Age- and Sex-Specific Trends in Fatal Incidence and Hospitalized Incidence of Stroke in Scotland, 1986 to 2005. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 475-483.	0.9	26
48	Type 2 diabetes remission: 2Âyear within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme. Diabetologia, 2020, 63, 2112-2122.	2.9	26
49	Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support. JMIR Research Protocols, 2020, 9, e15058.	0.5	24
50	Within-trial cost and 1-year cost-effectiveness of the DiRECT/Counterweight-Plus weight-management programme to achieve remission of type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2019, 7, 169-172.	5.5	22
51	The Costs and Benefits of Primary Total Hip Replacement:How Likely Are New Prostheses To Be Cost-effective?. International Journal of Technology Assessment in Health Care, 1998, 14, 743-761.	0.2	20
52	Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. Trials, 2015, 16, 267.	0.7	20
53	Enhancing Health Through Access to Nature: How Effective are Interventions in Woodlands in Deprived Urban Communities? A Quasi-experimental Study in Scotland, UK. Sustainability, 2019, 11, 3317.	1.6	20
54	Health impacts of environmental and social interventions designed to increase deprived communitiesâ€™ access to urban woodlands: a mixed-methods study. Public Health Research, 2019, 7, 1-172.	0.5	19

#	Article	IF	Citations
55	Cost-Effectiveness Acceptability Curves in the Dock. Medical Decision Making, 2007, 27, 93-95.	1.2	18
56	Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. Quality of Life Research, 2010, 19, 323-331.	1.5	16
57	ARE VALUE OF INFORMATION METHODS READY FOR PRIME TIME? AN APPLICATION TO ALTERNATIVE TREATMENT STRATEGIES FOR NSTEMI PATIENTS. International Journal of Technology Assessment in Health Care, 2013, 29, 435-442.	0.2	16
58	Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. Health Technology Assessment, 2022, 26, 1-174.	1.3	16
59	How effective is the Forestry Commission Scotland's woodland improvement programmeâ€"â€˜Woods In and Around Townsâ€™ (WIAT)â€"at improving psychological well-being in deprived urban communities? A quasi-experimental study. BMJ Open, 2013, 3, e003648.	0.8	15
60	Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators. Social Science and Medicine, 2016, 169, 141-148.	1.8	15
61	Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data. Medical Decision Making, 2020, 40, 460-473.	1.2	15
62	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. Wellcome Open Research, 0, 4, 108.	0.9	15
63	Ankle Injury Management (AIM): design of a pragmatic multi-centre equivalence randomised controlled trial comparing Close Contact Casting (CCC) to Open surgical Reduction and Internal Fixation (ORIF) in the treatment of unstable ankle fractures in patients over 60Âyears. BMC Musculoskeletal Disorders, 2014, 15, 79.	0.8	14
64	Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. Cost Effectiveness and Resource Allocation, 2015, 13, 19.	0.6	14
65	BEAT-IT: Comparing a behavioural activation treatment for depression in adults with intellectual disabilities with an attention control: study protocol for a randomised controlled trial. Trials, 2015, 16, 595.	0.7	14
66	Cost-Effectiveness Uncertainty Analysis Methods. Medical Decision Making, 2015, 35, 596-607.	1.2	14
67	The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia. Lancet Psychiatry,the, 2022, 9, 477-486.	3.7	13
68	Hospital Expenditure at the End-of-Life: What Are the Impacts of Health Status and Health Risks?. PLoS ONE, 2015, 10, e0119035.	1.1	12
69	The Design and Analysis of Stochastic Cost-Effectiveness Studies for the Evaluation of Health Care Interventions. Drug Information Journal, 2001, 35, 1455-1468.	0.5	11
70	A View from the Bridge: Health Economic Evaluation â€" A Valueâ€Based Framework?. Health Economics (United Kingdom), 2016, 25, 1499-1502.	0.8	10
71	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. Wellcome Open Research, 2019, 4, 108.	0.9	9
72	Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic. Pharmacoeconomics, 2021, 39, 1201-1208.	1.7	8

#	Article	IF	Citations
73	Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). Open Heart, 2016, 3, e000371.	0.9	7
74	Artificial neural network metamodel for sensitivity analysis in a total hip replacement health economic model. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 629-640.	0.7	7
75	Editorial. Health Economics (United Kingdom), 2016, 25, 6-8.	0.8	6
76	Using Nominal Group Technique to Identify Key Attributes of Oncology Treatments for a Discrete Choice Experiment. MDM Policy and Practice, 2019, 4, 238146831983792.	0.5	5
77	A quality-of-life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial. Journal of Medical Economics, 2020, 23, 64-69.	1.0	4
78	Economic evaluation of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: the CULPRIT-SHOCK trial. European Journal of Health Economics, 2020, 21, 1197-1209.	1.4	4
79	Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting. Oncology and Therapy, 2019, 7, 141-157.	1.0	3
80	Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review. BMJ Open, 2020, 10, e034209.	0.8	3
81	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. Wellcome Open Research, 0, 4, 108.	0.9	3
82	Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis. Clinical Colorectal Cancer, 2021, 20, 236-244.	1.0	2
83	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 2022, 23, 307.	0.7	2
84	Unfinished Symphony: A Tribute to the Life and Career of Bernie Oâ€™Brien (1959â€“2004). Medical Decision Making, 2004, 24, 538-544.	1.2	1
85	Reply to â€˜Evidence is still required for treatment as prevention for riskier routes of HIV transmissionâ€™. Aids, 2010, 24, 2892-2893.	1.0	1
86	Protocol for an economic evaluation of the randomised controlled trial of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trial. BMJ Open, 2017, 7, e014849.	0.8	1
87	Application of a Mapping Function to Estimate Utilities for Ragweed Allergy Immunotherapy Trials. PharmacoEconomics - Open, 2020, 4, 649-655.	0.9	1
88	Health Economics in Asthma and COPD. , 2009, , 751-760.		0